IKT
NASDAQInhibikase Therapeutics Inc.
News · 26 weeks40-40%
2026-03-012026-08-23
Mix2590d
- Insider9(36%)
- Other8(32%)
- SEC Filings7(28%)
- Analyst1(4%)
Latest news
25 items- SECAmendment: SEC Form SCHEDULE 13G/A filed by Inhibikase Therapeutics Inc.SCHEDULE 13G/A - Inhibikase Therapeutics, Inc. (0001750149) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Inhibikase Therapeutics Inc.SCHEDULE 13G/A - Inhibikase Therapeutics, Inc. (0001750149) (Subject)
- SECSEC Form S-8 filed by Inhibikase Therapeutics Inc.S-8 - Inhibikase Therapeutics, Inc. (0001750149) (Filer)
- SECSEC Form 10-Q filed by Inhibikase Therapeutics Inc.10-Q - Inhibikase Therapeutics, Inc. (0001750149) (Filer)
- SECSEC Form 8-K filed by Inhibikase Therapeutics Inc.8-K - Inhibikase Therapeutics, Inc. (0001750149) (Filer)
- PRInhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent ActivityWILMINGTON, Del., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing IKT-001, a novel once-daily oral anti-proliferative for Pulmonary Arterial Hypertension ("PAH"), today reported financial results for the quarter ended June 30, 2026, and highlighted recent developments. "During our second quarter and in recent weeks we continued to advance our Phase 3 IMPROVE-PAH study with 26 country regulatory approvals together with the recent initiation of 43 clinical sites across a range of countries," said Mark Iwicki, Chief Executive Officer of Inhibikase. "Also, during the quarter, favorable
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Inhibikase Therapeutics Inc.SCHEDULE 13G/A - Inhibikase Therapeutics, Inc. (0001750149) (Subject)
- INSIDERLarge owner Ra Capital Management, L.P. disposed of 18,030,000 shares (SEC Form 4)4 - Inhibikase Therapeutics, Inc. (0001750149) (Issuer)
- INSIDERDirector Berman Dennis N exercised 21,854 shares at a strike of $1.26 (SEC Form 4)4 - Inhibikase Therapeutics, Inc. (0001750149) (Issuer)
- SECSEC Form 8-K filed by Inhibikase Therapeutics Inc.8-K - Inhibikase Therapeutics, Inc. (0001750149) (Filer)
- SECInhibikase Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Inhibikase Therapeutics, Inc. (0001750149) (Filer)
- PRInhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAHWILMINGTON, Del., July 23, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary Arterial Hypertension ("PAH"), today announced that the U.S. Food and Drug Administration ("FDA") has granted Orphan Drug Designation ("ODD") to its lead product candidate IKT-001, a prodrug of imatinib mesylate, for the treatment of PAH. "The grant of Orphan Drug Designation for IKT-001 by FDA is another important milestone for Inhibikase and reflects the high unmet medical need among the approximately 50,000 people suffering from PAH in the United States," said Mark Iwicki, Chief Executive
- INSIDERNew insider Ra Capital Management, L.P. claimed ownership of 25,000,000 shares (SEC Form 3)3 - Inhibikase Therapeutics, Inc. (0001750149) (Issuer)
- SECSEC Form SCHEDULE 13G filed by Inhibikase Therapeutics Inc.SCHEDULE 13G - Inhibikase Therapeutics, Inc. (0001750149) (Subject)
- SECSEC Form 8-K filed by Inhibikase Therapeutics Inc.8-K - Inhibikase Therapeutics, Inc. (0001750149) (Filer)
- PRInhibikase Therapeutics Announces Sale of $50 Million of Shares Through its At-the-Market (ATM) FacilityWILMINGTON, Del., July 14, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary Arterial Hypertension ("PAH"), today announced that it has sold 25,000,000 shares of the Company’s common stock to RA Capital Management through its at-the-market ("ATM") facility for gross proceeds of $50 million. The Company expects that the additional capital raised through this financing, together with existing cash reserves, will support operations through topline data readout in Part B of the Company’s ongoing global Phase 3 IMPROVE-PAH clinical study, subject to the full exercise of the o
- PRInhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)WILMINGTON, Del., July 02, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), today announced that the Company granted non-qualified stock options to purchase up to an aggregate of 981,243 shares of the Company’s common stock to seven newly-hired non-executive employees under the Company’s 2026 Inducement Equity Plan (the "Inducement Plan"), effective as of June 30, 2026 (the "Effective Date"). The inducement grants were previously approved by the Compensation Committee of the Company’s Board of Directors, as a material inducement to the new employees’ entry into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).The
- INSIDERSEC Form 4 filed by Director Berman Dennis N4 - Inhibikase Therapeutics, Inc. (0001750149) (Issuer)
- INSIDERSEC Form 4 filed by Director Aurentz Vincent4 - Inhibikase Therapeutics, Inc. (0001750149) (Issuer)
- INSIDERSEC Form 4 filed by Director Bellini Roberto4 - Inhibikase Therapeutics, Inc. (0001750149) (Issuer)
- INSIDERSEC Form 4 filed by Director Munshi Amit4 - Inhibikase Therapeutics, Inc. (0001750149) (Issuer)
- INSIDERSEC Form 4 filed by Director Kush Arvind4 - Inhibikase Therapeutics, Inc. (0001750149) (Issuer)
- INSIDERSEC Form 4 filed by Director Canner David4 - Inhibikase Therapeutics, Inc. (0001750149) (Issuer)
- SECInhibikase Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Inhibikase Therapeutics, Inc. (0001750149) (Filer)
- ANALYSTOppenheimer initiated coverage on Inhibikase Therapeutics with a new price targetOppenheimer initiated coverage of Inhibikase Therapeutics with a rating of Outperform and set a new price target of $5.00
IKT FAQ
7 questionsWhat does Inhibikase Therapeutics Inc. do?
Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia and neurogenic constipation; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects...Where does IKT stock trade?
Inhibikase Therapeutics Inc. (IKT) is listed on NASDAQ.What sector and industry is IKT in?
Inhibikase Therapeutics Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Inhibikase Therapeutics Inc. go public?
Inhibikase Therapeutics Inc. (IKT) completed its IPO in 2020.What are analysts saying about IKT?
Inhibikase Therapeutics Inc. has had 7 recent analyst actions on file. The most recent action was from Oppenheimer: Outperform with a $500.00 price target on 2026-06-10. Recent price targets range from $400.00 to $1200.00.What companies are similar to IKT?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare IKT side-by-side with any of them on Quantisnow.How can I track IKT on Quantisnow?
Quantisnow aggregates Inhibikase Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow IKT to receive live email and push alerts on every new disclosure.